Telisotuzumab vedotin for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 May 2018: Trial registered, NCT03539536
  2. 10 Oct 2018: Trial started, NCT03539536

The trials

NCT03539536: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

State
Under way
Phase
Phase 2
People
270 taking part
Started
10 Oct 2018
Primary completion
Jul 2026
Arms
Telisotuzumab vedotin
Results
None posted
  1. 29 May 2018: Trial registered
  2. 10 Oct 2018: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.